Oatp(有机阴离子转运多肽)介导的转运:阿托伐他汀在卒中中神经保护作用的机制
研究在大鼠大脑中动脉闭塞再灌注模型中,评估Oatp1a4介导阿托伐他汀跨血脑屏障转运对其神经保护作用的影响。单次静脉注射阿托伐他汀可减少梗死体积、减轻脑水肿、增加尾壳核神经元核表达并改善神经功能,而Oatp抑制剂非索非那定可减弱上述效应,提示阿托伐他汀的神经保护可能依赖Oatp介导的中枢递送。
要点
- 大鼠大脑中动脉闭塞90分钟后,缺血脑组织对氚标记阿托伐他汀的摄取增加。
- 单次静脉注射阿托伐他汀20 mg/kg可减少梗死体积、降低脑水肿比并改善神经功能。
- Oatp抑制剂非索非那定可减弱阿托伐他汀的全部有益效应,提示转运依赖性。
核心结论
- 阿托伐他汀的神经保护作用可能依赖Oatp介导的跨血脑屏障中枢递送,该机制在缺血性卒中血脑屏障通透性增加时仍持续存在。
- 这些转化研究发现支持利用血脑屏障转运体递送神经保护药物。
研究设计与样本
- 雄性Sprague-Dawley大鼠(200-250 g)接受大脑中动脉闭塞90分钟后再灌注,最长观察7天。
- 在拔除血管内缝线后2小时静脉注射阿托伐他汀20 mg/kg。
- 使用Oatp竞争性抑制剂非索非那定3.2 mg/kg静脉注射判断Oatp介导转运的参与。
- 采用原位脑灌注测定Oatp1a4转运活性,用2,3,5-氯化三苯基四氮唑染色脑切片和共聚焦显微镜分别评估梗死体积/脑水肿比和神经元核表达,用神经功能缺损评分和转棒分析评估功能结局。
主要发现
- 大脑中动脉闭塞后2小时,缺血脑组织中氚标记阿托伐他汀摄取增加。
- 单次阿托伐他汀剂量显著减少大脑中动脉闭塞后梗死体积、降低脑水肿比、增加尾壳核神经元核表达并改善功能性神经结局。
- 非索非那定共同给药减弱了阿托伐他汀的所有大脑中动脉闭塞阳性效应。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug discovery for stroke is challenging as indicated by poor clinical translatability. In contrast, HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (ie, statins) improve poststroke neurological outcomes. This property requires transport across the blood-brain barrier via an endogenous uptake transporter (ie, Oatp1a4 [organic anion transporting polypeptide 1a4]). Our goal was to study Oatp1a4 as a drug delivery mechanism because the blood-brain barrier cannot be assumed to be completely open for all drugs in ischemic stroke. METHODS: Male Sprague-Dawley rats (200-250 g) were subjected to middle cerebral artery occlusion (90 minutes) followed by reperfusion for up to 7 days. Atorvastatin (20 mg/kg, IV) was administered 2 hours following intraluminal suture removal. Involvement of Oatp-mediated transport was determined using fexofenadine (3.2 mg/kg, IV), a competitive Oatp inhibitor. Oatp1a4 transport activity was measured by in situ brain perfusion. Infarction volumes/brain edema ratios and neuronal nuclei expression were determined using 2,3,5-triphenyltetrazolium chloride-stained brain tissue slices and confocal microscopy, respectively. Poststroke functional outcomes were assessed via neurological deficit scores and rotarod analysis. RESULTS: At 2-hour post-middle cerebral artery occlusion, [3H]atorvastatin uptake was increased in ischemic brain tissue. A single dose of atorvastatin significantly reduced post-middle cerebral artery occlusion infarction volume, decreased brain edema ratio, increased caudoputamen neuronal nuclei expression, and improved functional neurological outcomes. All middle cerebral artery occlusion positive effects of atorvastatin were attenuated by fexofenadine coadministration (ie, an Oatp transport inhibitor). CONCLUSIONS: Our data demonstrate that neuroprotective effects of atorvastatin may require central nervous system delivery by Oatp-mediated transport at the blood-brain barrier, a mechanism that persists despite increased cerebrovascular permeability in ischemic stroke. These novel and translational findings support utility of blood-brain barrier transporters in drug delivery for neuroprotective agents.
引用
- Williams EI, Betterton RD, Stanton JA, et al. Oatp (Organic Anion Transporting Polypeptide)-Mediated Transport: A Mechanism for Atorvastatin Neuroprotection in Stroke. Stroke. 2023. PMID: 37750296. doi:10.1161/STROKEAHA.123.043649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。